Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-12-23 Earnings Release
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis a présenté le programme OBA dans l'obésité lors du 17ème congrès international de la SCWD
Earnings Release Classification · 99% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces the presentation of clinical program data (OBA program for obesity) at an international congress (SCWD). It details study results (Quinolia) and outlines plans for a future Phase 2 study (OBA study starting in 2025). This format, which summarizes recent corporate/scientific news and often includes forward-looking statements and contact information, is characteristic of an Earnings Release (ER) or a general press release announcing significant operational updates. Since it focuses on presenting clinical data and future study plans rather than just the final quarterly financial figures, it aligns best with the 'Earnings Release' category, which often encompasses key operational and scientific milestones announced via press release, or potentially a Regulatory Filing (RNS) if it were less specific. Given the focus on presenting results and upcoming trials, ER is the most appropriate fit among the specific operational codes, as it is a formal announcement of recent developments, even if not strictly quarterly financials. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). FY 2024
2024-12-23 French
Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor Call
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces the company's participation in a congress and the hosting of an "Obesity Investor Call." This is an announcement about an upcoming event where company information (strategy, clinical data) will be discussed, rather than the full transcript of the call itself (CT) or a formal regulatory filing like a 10-K or ER. Since it is an announcement related to investor engagement and future presentations, it most closely aligns with an Investor Presentation (IP) or a general announcement. Given the context of announcing participation in an event where strategic positioning will be presented, 'Investor Presentation' (IP) is a strong fit, as these press releases often precede or summarize such events. However, because the core content is announcing an *event* (a call/session) and not the presentation materials themselves, and it is a general press release format, it could also be considered a Regulatory Filing (RNS) if IP is too specific. Since the content focuses heavily on upcoming investor engagement and strategic updates, IP is the most descriptive category for the *subject matter* being announced. Given the short length and the nature of announcing an event where information will be shared, it is not the full report itself. I will classify it as an Investor Presentation (IP) announcement, as the focus is on the content to be presented to investors.
2024-12-02 English
Biophytis participe à la 17ème édition du congrès SCWD et organise un Obesity Investor Call
Report Publication Announcement Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces the company's participation in a medical congress (SCWD) and the organization of an "Obesity Investor Call" featuring expert panelists and company executives. This type of announcement, which details upcoming investor events, presentations, or participation in industry conferences, is best classified as a general announcement related to investor relations or corporate activity that doesn't fit the strict definitions of an Earnings Release (ER), Interim Report (IR), or a specific regulatory filing like 10-K or DEF 14A. Since it is a press release announcing an event aimed at investors and analysts, it aligns most closely with a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate press releases that don't fit the highly specific categories like DIV, ER, or CT. However, the content is specifically about an investor event/call, which often falls under general investor communication. Since there is no specific code for 'Investor Event Announcement', and it is not a transcript (CT), earnings release (ER), or a formal report (10-K, IR), RNS serves as the best general regulatory/corporate announcement category.
2024-12-02 French
Biophytis publie ses comptes semestriels et fait le point sur ses activités
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Biophytis titled 'Biophytis publie ses comptes semestriels et fait le point sur ses activités' (Biophytis publishes its half-year accounts and provides an update on its activities). It contains a summary of financial results for the first half of 2024, including tables for the income statement and balance sheet, alongside management commentary on business developments, clinical trials, and outlook. Since it provides comprehensive financial data for a period shorter than a full fiscal year (half-year), it is classified as an Interim/Quarterly Report. H1 2024
2024-09-30 French
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Earnings Release Classification · 95% confidence The document is a press release from Biophytis SA announcing its first-half 2024 financial results. It includes key highlights, management commentary, and summarized financial statements (income statement and balance sheet). While it contains financial data, it is structured as an initial announcement of results rather than a full, comprehensive interim report. According to the filing definitions, this fits the 'Earnings Release' (ER) category, as it provides the initial announcement of periodical financial results with key highlights. H1 2024
2024-09-30 English
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release" and announces a specific corporate event: signing two partnership contracts in Asia to deploy its drug candidate BIO101. This is a material, non-financial announcement regarding business strategy and development. It is not a formal regulatory filing like a 10-K, an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). Since it is a general, timely announcement of business operations that doesn't fit the highly specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate classification is the general regulatory announcement/press release category, which is RNS (Regulatory Filings), as per the provided definitions, especially since it is not a formal financial report.
2024-07-22 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.